This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to characterize the role of germline genetic variation and viral infection in the development and progression of pediatric acute myeloid leukemia (AML). The $101,948 award to the Van Andel Research Institute (VAI) will fund efforts to identify germline variants that may predispose individuals to high-risk pediatric AML, including functional validation using a zebrafish model. The research will also investigate how germline regulatory, splicing, and structural variants, as well as viral genomic integrations, may serve as catalysts of leukemia risk. This project aims to establish the scientific and professional foundation for the awardee's career as an independent researcher in this critical area of pediatric cancer research.
Generated 3/25/25, 3:39 AM